Orphan Drugs & Rare Diseases & Rare Diseases Global Congress 2021 Europe | PGE Group
Time 2022-09-03 09:30:24Web Name: Orphan Drugs & Rare Diseases & Rare Diseases Global Congress 2021 Europe | PGE Group
WebSite: http://www.orphandrugscongress.com
ID:301930
Keywords:
Rare,Diseases,amp,OrphanDescription:
Skip to contentFeaturing
16th Orphan Drugs & Rare Diseases Global Congress 2022 Europe
Delivering Innovative Therapies to Patients with Rare Diseases
Days Hours Minutes Seconds16th - 18th February 2022 - Pre - Conference Workshop + 2 Days Conference
Holiday Inn Bloomsbury, an IHG Hotel, Coram St, London, WC1N 1HT, UK
Exhibit & Sponsor OpportunitiesPharma Conference London UK
16th Orphan Drugs & Rare Diseases Global Congress 2022
Paradigm Global Events is again proud to present our Orphan Drugs and Rare Diseases 2022 Europe. It’s the 16th in the series of our Flagship tri-annual Orphan Drugs and Rare Diseases event, this congress will provide you with a comprehensive overview of the critical issues shaping the future of Orphan Drugs.
The conference will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top-tier government, pharmaceuticals, biotechs, non-profit organizations, orphan drugs developers, research organizations as well as patient groups and advocates. We are putting together an agenda that address the driving macroeconomic factors, policies, and issues that will steer the development of orphan drugs globally including access, commercialization, collaborations, policies, reimbursement, pricing, and more.
The two-day Congress will provide an interactive, cutting edge, and comprehensive discussion
and networking format led by key experts with intimate knowledge in the industry. Gain
practical strategies and best practices on challenges, innovations, technologies, and
concepts surrounding orphan drugs and rare diseases.
We look forward to welcoming you to the congress!
Key Industry Experts Speakers
Doug Danison
Head of Europe, bluebird bio
Pedro Franco
Director for Global Regulatory & Scientific Policy (GRASP), Merck
Emily Crossley
Co-founder, Duchenne UK
Femida Gwadry-Sridhar
CEO and Founder, Pulse Infoframe Inc.
From a patient advocacy organization perspective, was a very informative meeting. Learned a lot from presentations and networking that will inform how we can add value to the advocacy-patient-drug developer dialogue.
Scientific Director, Research, Association for Frontotemporal Degeneration
I was very impressed with the format, the content was interesting and well done. I felt I learned a lot and was glad to be able to attend.
Business Development at Pharm-Olam, LLC
Introducing
2022 CONFERENCE FORMAT
Orphan Drugs & Rare Diseases Global Congress 2022 – choose your focus streams in the afternoon of both conference days by attending keynotes, presentations, and group discussions that have the most relevance to you. Choose from…
Commercialization, Current Trends and Collaborations
Commercialization, Current Trends and Collaborations
Access, Pricing and Reimbursement
Access, Pricing and Reimbursement
Innovations, Discovery and Clinical Development
Innovations, Discovery and Clinical Development
Advance Therapy Medicinal Products
Advance Therapy Medicinal Products
Orphan Drugs & Rare Diseases 2022 Europe
Sponsors
Paradigm Global Events are again proud to present the Orphan Drugs and Rare Diseases 2022 Europe. It’s the 16th in the series of our Flagship tri-annual Orphan Drugs and Rare Diseases event, this congress will provide you with a comprehensive overview of the critical issues shaping the future of Orphan Drugs.
The COVID-19 Pandemic has impacted the lives of just about everyone, patients receiving continuous treatment and care included. The Rare Disease community is already experiencing considerable challenges in achieving early and detailed diagnosis and having access to care and life-saving treatment, to chronic, highly complex, progressive, and severely disabling nature of their diseases, which generate specific care needs. Undoubtedly, during this crisis, the rare diseases community is experiencing unprecedented overall disruption even more…
According to a report by Fortune Business Insights, the Global Orphan Drugs Market size will emerge from the COVID-19 crisis at a moderate growth during the forecast period of 2020 to 2026. The global orphan drugs market size is projected to reach USD 340.84 billion by the end of 2027. As stated, the market was worth USD 151.00 billion in 2019 and will exhibit a CAGR of 10.5% during the forecast period, 2020-2027.
The current regulatory climate increasing the number of regulatory approvals, expanding numbers of successful clinical trials related to these drugs, tremendous investments in R & D, and also the interest and existence of a number of large-scale manufacturers, will create opportunities and contribute exponentially to the overall market growth.
The two-day Congress will provide an interactive, cutting edge, and comprehensive discussion and networking format led by key experts with intimate knowledge in the industry. Gain practical strategies and best practices on challenges, innovations, technologies, and concepts surrounding orphan drugs and rare diseases. We look forward to welcoming you to the congress!
Jocelyn Raguindin
Jocelyn is Conference Director at Paradigm Global Events (PGE). She has over 15+ years experience in organizing pharma-industry conferences and has been at the helm of every PGE conference since 2013. Jocelyn is based in London, UK.
Gain Latest Insights on:
Current Orphan Drugs landscape and implications of COVID19Major drivers in global rare disease marketKey developmental strategies carried out and Influencing factors that may affect market share to stand out in this industryHow the MHRA managing orphan medicinal products after Brexit?Finding innovative and alternative ways in funding the development of Orphan DrugsPatients perspective: what really matters to rare disease patients and caregivers?Key authorities facilitating development and approval of diagnostic products/servicesComing Together in Developing Orphan Drugs and Crossing BordersTrends and evolution of Advanced Therapy Medicinal ProductsHow Can the Developer and the Patient Assist in the Evolution and Development of Orphan Drugs to make it accessible to patients in a shorter period of time?Strategies to improve Access and AffordabilityWhat Do Developers Look for When Looking for an Outsourcing Partner?What Do Insurance Companies Think About Orphan Drugs? Will They Make Modifications to Their Policies to Support Patients with Rare Diseases?Opportunity to network with Peers, potential Partners, and InvestorsmYou Will Meet:
Presidents, Heads/Chiefs, Directors, VPs and Managers in the are of:Research and DevelopmentPersonalised MedicineRegenerative MedicineExternal R&D InnovationInnovative MedicineRare and Ultra-Rare Diseases Cell and Gene TherapyTranslational ScienceMolecular GeneticistProgram ManagementPatient Advocacy GroupsPublic AffairsMedical AffairsRegulatory AffairsClinical Research OrganizationsMarket AccessPricing and ReimbursementHealth Economics Outcomes ResearchCommercial DevelopmentInvestments and FundingProduct SpecialistsGlobal Strategic ServicesBusiness Planning and OperationsPharmaciesAcademiaDoug Danison
Head of Europe, bluebird bio
Doug Danison is the Head of Europe at bluebird bio since January 2021. He joined bluebird bio in July 2015 to establish the global pricing, market access, and health economics team known as Access Value & Evidence Strategy (AVES).
Doug has more than 20 years of Pricing & Market Access experience, including roles with Eli Lilly & Company, Amgen, Millennium/Takeda Oncology. In that time, he has led or overseen the preparation of market access strategies for products in early development, pivotal study planning, launch, and post-launch lifecycle management. While addressing market access challenges from a variety of vantage points including Global, European Regional, and U.S. roles he’s built teams, processes, and a knowledge base that enables the execution of market access strategies that anticipate and meet the needs of access decision-makers in an increasingly challenging market access environment.
Pedro Franco
Director for Global Regulatory & Scientific Policy (GRASP), Merck
Pedro Franco holds a degree in Pharmacy (PharmD) from the University of Lisbon, a Master in Organic Chemistry (M.Sc) from the New University of Lisbon with collaboration with Imperial College in London, and a Ph.D. in Orphan drugs and Rare diseases from the University of Sheffield. Pedro Franco completed also his music studies (Cello) in Lisbon.
Currently, Pedro is working as a Director for Global Regulatory & Scientific Policy (GRASP) at Merck, and he is mainly focused on regulatory intelligence, strategy, and policy. In addition, he is the liaison for the China and Latam region concerning regulatory and policy topics. Previously, He worked at the European Medicines Agency for 12 years in different roles and departments mainly focusing on regulatory affairs, international collaboration, assessment, authorisation of medicines, orphan drugs, paediatrics, peer review, quality, and strategy. Beforehand, he was working at INFARMED (the Portuguese national competent authority) as a pharmaceutical assessor. Before joining regulatory competent authorities, he worked as a post-graduate research fellow in the area of toxicology, carcinogenic chemistry, and drug development.
Emily Crossley
Co-founder, Duchenne UK
Emily Crossley is the co-founder and joint CEO of Duchenne UK. She graduated from Oxford University with a degree in modern history and became a reporter and anchor for Channel 4 News and CNN International. After her eldest son was diagnosed with Duchenne Muscular Dystrophy (DMD), she set up the Duchenne Children’s Trust. The charity joined forces with Joining Jack and is now Duchenne UK. In 7 years Duchenne UK has committed £14 million to funding treatments and a cure for DMD. Emily helped to create the Duchenne Dash, an iconic 24-hour bike ride from London to Paris to raise money and awareness for DMD. This year the Duchenne Dash raised over £1.2 million. Emily has advocated on behalf of patients around the world. She has represented the patient community in meetings at the EMA, the MHRA, the FDA, and NICE. She has spoken at Parliamentary meetings and was praised in the House of Commons for the charity’s work, by the Minister for Life Sciences, George Freeman MP. She is a member of the MHRA patient group consultative forum.
<<< Thank you for your visit >>>
Websites to related : AWDperformanceparts.com - Subaru
Skip to content 610.751.2519 My Account 0 Back My Account Shop by Vehicle Shop By CategoryEngineAir InductionAir Oil SeparatorCoolingEngine
Neurodermitis-campus – DAA Mit dem Laden des Videos akzeptieren Sie die Datenschutzerklärung von Vimeo.
Mehr erfahren Video laden Vimeo immer entsperren Hallo, ich bin Manf
Skip to contentFacebookInstagramVOLUNTEERDONATEExploreFood & DiningShoppingServicesCommunity GroupsParkingProjectsEventsAboutWho We AreOur BylawsBoard
Sensors & IoT Infrastructure | DBox Truck Ramps | 866-923-0027
Load a Mower on ANY Box Truck with the MR-750 Manual Loading Ramp... Easy, Bolt-On Installation! We Ship Anywhere! 866-923-0027 Get your FREE quo
Crane Rental | Crane Parts & Ser(608) 630-97804981 Cake Parkway, Deforest, WIJOB OPPORTUNITIESCONTACT US0 Items PARTS AND SERVICERENT EQUIPMENTHOMEOUR COMPANYOur CompanyHistoryCont
Business & Time – İş DüDon't MissMetawear Token Nedir?Altın Fiyatları Düşüşte…Fonlar Çıkışı Teknoloji Ve Bankacılıkta Arıyor…Borsa İstanbul’da Ha
Imatra Base Camp | Imatra Base CHyppää pääsisältöön .cls-1{fill:#f3724a;}.cls-2{fill:#231f20;}Imatra logo Imatra Base Cam
McDonogh Village Apartments & ToPhone Number (410) 922-4900
1, 2 & 3 Bedroom Apartments in PPhone Number (410) 484-5700
adsHot Websites